Nuance Pharma's Ohtuvayre Shows Improved Lung Function in Chinese COPD Patients - ENHANCE-CHINA Phase 3 Results Published

Key Takeaways

• CHEST journal published positive Phase 3 ENHANCE-CHINA trial results for Ohtuvayre (ensifentrine) in COPD treatment
• Study demonstrated improved lung function in Chinese adult patients with chronic obstructive pulmonary disease
• Publication in peer-reviewed journal strengthens regulatory pathway for Nuance Pharma’s respiratory drug candidate

---

Nuance Pharma announced April 20, 2026, that CHEST, the official journal of the American College of Chest Physicians, has published results from its Phase 3 ENHANCE-CHINA trial evaluating Ohtuvayre® (ensifentrine) for chronic obstructive pulmonary disease (COPD) treatment.

The peer-reviewed publication reports that Ohtuvayre helped improve lung function in Chinese adult patients with COPD, marking a significant milestone for Nuance Pharma’s respiratory medicine portfolio. The ENHANCE-CHINA trial represents the company’s successful expansion into the Chinese market, where COPD affects millions of patients.

Clinical Significance and Market Impact

The publication in CHEST, a leading respiratory medicine journal, validates the clinical efficacy of ensifentrine in a diverse patient population. COPD remains a leading cause of morbidity and mortality globally, with particularly high prevalence in China due to environmental factors and smoking rates.

Ensifentrine’s mechanism of action as a dual phosphodiesterase 3 and 4 inhibitor offers a novel approach to COPD management, potentially providing both bronchodilator and anti-inflammatory effects in a single therapy.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Regulatory and Commercial Implications

The successful Phase 3 results in Chinese patients strengthen Nuance Pharma’s regulatory submissions in multiple markets. Publication in a prestigious peer-reviewed journal adds scientific credibility and may accelerate regulatory review processes.

For investors and healthcare providers, these results demonstrate Ohtuvayre’s potential as a differentiated COPD treatment option. The Chinese market represents significant commercial opportunity, with the country’s aging population and high COPD burden creating substantial unmet medical need.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Next Steps

Nuance Pharma is expected to leverage these published results in ongoing regulatory discussions with health authorities. The company continues advancing its global development program for ensifentrine across multiple respiratory indications.

---

Frequently Asked Questions

What does this mean for COPD patients?

The positive results suggest Ohtuvayre could provide a new treatment option that improves lung function, though the drug still requires regulatory approval before becoming available to patients.

When will Ohtuvayre be available in China?

The timeline depends on regulatory approval processes. Nuance Pharma will need to complete submissions to Chinese health authorities and receive marketing authorization before commercial availability.

How does ensifentrine compare to existing COPD treatments?

Ensifentrine works as a dual PDE3/4 inhibitor, offering both bronchodilator and anti-inflammatory effects in one drug, potentially providing advantages over current single-mechanism therapies.

Related coverage

• Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses
• Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease
• Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update